Biotech & Genetics · Projected milestone

First in-body CRISPR drug approved

Estimated year~2027

85% by 2028 · including earlier years

The year is an editorial timing estimate. The percentage applies to occurrence by the stated deadline. These estimates are not calibrated odds.

A named major regulator approves an in-vivo CRISPR editing medicine; the likely near-term candidate is lonvoguran ziclumeran for hereditary angioedema.

Explore this milestone on the interactive map

What the forecast means

Milestone stage: regulatory approval

Pivotal HAE efficacy is reported and filing accepted; lifelong prevention is not established

Timing window: 2027–2028. An editorial range, not a statistical confidence interval.

Completion criteria: A named major regulator approves an in-vivo CRISPR editing medicine; the likely near-term candidate is lonvoguran ziclumeran for hereditary angioedema. A forecast, policy target or prototype outside this definition does not resolve it.

This page describes a forecast, rather than an achieved result. Read the methodology and assumptions.

Built on

CRISPR gene editingRecorded · 2012enables
Lipid nanoparticle drugsRecorded · 2018enables
First CRISPR therapyRecorded · 2023enables

Led to

VERVE-102 in-body cholesterol editing demonstratedRecorded · 2026influences

Sources & evidence

Intellia FDA acceptance and priority review release filed with SEC 2026-09-08
Intellia’s September 2026 SEC-filed release reports BLA acceptance and priority review for lonvo-z, a target action date of 2027-03-10, and a six-month pivotal efficacy window. It does not establish approval or lifelong prevention.

Original node: Claude. Definition and evidence revision: Astra. Cited researchers and institutions retain achievement credit.

Record reviewed 2026-10-18